High CDC20 levels increase sensitivity of cancer cells to MPS1 inhibitors

EMBO Rep. 2025 Feb;26(4):1036-1061. doi: 10.1038/s44319-024-00363-8. Epub 2025 Jan 21.

Abstract

Spindle assembly checkpoint (SAC) inhibitors are a recently developed class of drugs, which perturb chromosome segregation during cell division, induce chromosomal instability (CIN), and eventually lead to cell death. The molecular features that determine cellular sensitivity to these drugs are not fully understood. We recently reported that aneuploid cancer cells are preferentially sensitive to SAC inhibition. Here we report that sensitivity to SAC inhibition by MPS1 inhibitors is largely driven by the expression of CDC20, a main mitotic activator of the anaphase-promoting complex (APC/C), and that the effect of CDC20 is larger than that of the APC/C itself. Mechanistically, we discovered that CDC20 depletion prolongs metaphase duration, diminishes mitotic errors, and reduces sensitivity to SAC inhibition. We found that aneuploid cells express higher basal levels of CDC20, which shortens the duration of metaphase and leads to multiple mitotic errors, resulting in increased long-term sensitivity to the additional CIN induced by SAC inhibition. Our findings propose high CDC20 expression as a molecular feature associated with the sensitivity to SAC inhibition therapy and as a potential aneuploidy-induced cellular vulnerability.

Keywords: Aneuploidy; Cancer; Cell Cycle; Chromosomal Instability; Spindle Assembly Checkpoint (SAC).

MeSH terms

  • Anaphase-Promoting Complex-Cyclosome / metabolism
  • Aneuploidy
  • Antineoplastic Agents / pharmacology
  • Cdc20 Proteins* / genetics
  • Cdc20 Proteins* / metabolism
  • Cell Cycle Proteins* / antagonists & inhibitors
  • Cell Cycle Proteins* / genetics
  • Cell Cycle Proteins* / metabolism
  • Cell Line, Tumor
  • Chromosomal Instability / drug effects
  • Humans
  • M Phase Cell Cycle Checkpoints / drug effects
  • Metaphase / drug effects
  • Mitosis / drug effects
  • Neoplasms* / genetics
  • Neoplasms* / metabolism
  • Neoplasms* / pathology
  • Protein Serine-Threonine Kinases* / antagonists & inhibitors
  • Protein Serine-Threonine Kinases* / genetics
  • Protein Serine-Threonine Kinases* / metabolism
  • Protein-Tyrosine Kinases* / antagonists & inhibitors
  • Protein-Tyrosine Kinases* / genetics
  • Protein-Tyrosine Kinases* / metabolism

Substances

  • Cdc20 Proteins
  • Cell Cycle Proteins
  • TTK protein, human
  • CDC20 protein, human
  • Protein-Tyrosine Kinases
  • Protein Serine-Threonine Kinases
  • Anaphase-Promoting Complex-Cyclosome
  • Antineoplastic Agents